TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00306787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famciclovir
Description: Famciclovir 500 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Description: Valacyclovir 500 mg capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching famciclovir
Description: Famciclovir placebo, matching in size, color and forms of famciclovir tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching valacyclovir
Description: Valacyclovir placebo, matching in size, color and forms of valacyclovir capsule.
Study: NCT04616001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG
Description: Patients will receive IVIG daily for four days.
Study: NCT04415021

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Diaphragmatic and İliopsoas Myofascial Release Techniques
Description: Subjects in this arm will receive different myofascial release techniques aimed to relaxation the myofascial tension of the diaphragmatic and iliopsoas muscles.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Sham Myofascial Release Techniques
Description: Subjects in this arm will receive the same manual techniques of the diaphragmatic and iliopsoas myofascial release group, but without the myofascial stimulus.
Study: NCT03623659

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser assisted hatching
Description: After warming, blastocysts are subjected to laser assisted hatching (LAH) following the standard procedure.The LAH procedure lasts one minute per blastocyst.
Study: NCT02436902

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE is performed one month after resection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib is submitted one month after resection.

Intervention type: DRUG
Group type: OTHER
Intervention: TACE plus sorafenib
Description: TACE plus sorafenib will be submitted one month after resection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: empty control
Description: This group will not receive adjuvant therapy.

Intervention type: OTHER
Group type: OTHER
Intervention: empty control
Description: This group will not receive adjuvant therapy.
Study: NCT02650622

Intervention type: PROCEDURE
Intervention: Skin Biopsy
Description: Skin biopsy will only be performed on the proband children in the cohort 3. A small piece of skin (less than 1/8'') will be removed using a local anesthetic cream and a punch, which will then be used for culture of skin cells and other laboratory tests on metabolic function.
Study: NCT01540084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered in both groups. In the cocktail group, one milligram per kilogram body weight of 1% propofol emulsion (Baxter Healthcare Corp., Irvine, CA) was slowly infused by an automated pump (Terufusion syringe pump TE-331, Terumo Corporation, Tokyo, Japan). To maintain conscious level of patient in the conventional group to be at moderate or deep level, 25 mg of meperidine and/or 2.5 mg of midazolam were administered as necessary, whereas patients in the cocktail group were continuously administered with 1% propofol at the rate of 1 mg/kg/hr. An additional 0.5 mg/kg bolus was administered as needed to achieve the designed conscious level.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered in both groups. In the cocktail group, one milligram per kilogram body weight of 1% propofol emulsion (Baxter Healthcare Corp., Irvine, CA) was slowly infused by an automated pump (Terufusion syringe pump TE-331, Terumo Corporation, Tokyo, Japan). To maintain conscious level of patient in the conventional group to be at moderate or deep level, 25 mg of meperidine and/or 2.5 mg of midazolam were administered as necessary, whereas patients in the cocktail group were continuously administered with 1% propofol at the rate of 1 mg/kg/hr. An additional 0.5 mg/kg bolus was administered as needed to achieve the designed conscious level.
Study: NCT02106143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RejuvenAir™ Radial Spray Cryotherapy
Description: Metered dose radial spray cryotherapy treatment
Study: NCT03267602

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: If following patients are suffering from sleep apnea and agree to receive treatment,~1. older than 18 years, AHI\> 15 and present obvious symptoms or~2. less than 18 years, AHI still\> 5 after tonsillectomy and present obvious symptoms.~Investigators will process CPAP treatment for 3 months, and do neuropsychological assessment and sleep examination after treatment for 6 months.
Study: NCT01082393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical tacrolimus treatment
Description: 4 applications (day 1,day 3, day 6 and day10)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical pimecrolimus treatment
Description: 4 applications (day 1, day 3, day 6 and day 10)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local mometasone furoate treatment
Description: 4 applications (day 1, day 3, day 6 and day 10)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cold cream
Description: 4 applications (day 1, day 3, day 6 and day 10)
Study: NCT04205656

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leukocyte-Poor Platelet Rich Plasma (LP-PRP)
Description: Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the vein.
Study: NCT00761917

Intervention type: DEVICE
Intervention: Tear Film Analyzer
Description: tear film images

Intervention type: DEVICE
Intervention: Tear Film Analyzer
Description: tear film images
Study: NCT04823559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ThinkCancer workshop
Description: The proposed intervention, the ThinkCancer! Workshop, is practice-based and consists of themed sessions for both clinical and non-clinical staff, the co-production of a Cancer Safety Netting Plan (CSNP) and the appointment of a Cancer Safety Netting Champion (CSNC). The workshop aims to raise awareness and increase knowledge around current cancer diagnosis guidance and will be delivered over half a day during GP protected time in the form of face-to-face educational sessions. Sessions will consist of a series of interactive activities exploring existing processes within practices and developing plans for change to implement each component.
Study: NCT04493918

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem cell + Nacl 0.9%
Description: Patient who undergo surgery, debridement, decompression and posterior stabilization injection with Nacl 0.9% 2 ml + MSC 30 million unit

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NaCl 0.9%
Description: Patient who undergo surgery, debridement, decompression and posterior stabilization injection with Nacl 0.9% 2 ml
Study: NCT02881190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Study: NCT03194074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: In propofol/remifentanil group, propofol at a rate 75\~150 µg/kg/min and remifentanil at 0.1-0.3 µg/kg/min are maintained throughout surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: In desflurane/remifentanil group, desflurane at end tidal concentration at 0.7\~1.0 minimum alveolar concentration (MAC) and remifentanil 0.1-0.3 ug/kg/min are used.
Study: NCT04114136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab or Pembrolizumab (dependent upon approved indication)
Description: Anti-PD-1 mAb (monoclonal antibody)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab or Pembrolizumab (dependent upon approved indication)
Description: Anti-PD-1 mAb (monoclonal antibody)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab or Pembrolizumab (dependent upon approved indication)
Description: Anti-PD-1 mAb (monoclonal antibody)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Acts directly or indirectly on the liver to lower glucose production, and acts on the gut to increase glucose utilisation, increase GLP-1 and alter the microbiome.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: A member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity. Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).
Study: NCT01672294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preparation and life completion
Description: Caregiver subjects will discuss life review, issues of forgiveness and heritage and legacy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Caregiver subjects will listen to a non-guided relaxation CD with facilitator.
Study: NCT03797989

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. vivax infected inoculum (parasitised red blood cells)
Description: In the first controlled human malaria infection (CHMI, Phase A), inoculation of parasitised red blood cells will be at three different doses (1 vial, 1:5 dilution, 1:20 dilution). The optimal inoculation dose will then be selected and administered to all participants in each of the second and third CHMI.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. vivax infected inoculum (parasitised red blood cells)
Description: In the first controlled human malaria infection (CHMI, Phase A), inoculation of parasitised red blood cells will be at three different doses (1 vial, 1:5 dilution, 1:20 dilution). The optimal inoculation dose will then be selected and administered to all participants in each of the second and third CHMI.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. vivax infected inoculum (parasitised red blood cells)
Description: In the first controlled human malaria infection (CHMI, Phase A), inoculation of parasitised red blood cells will be at three different doses (1 vial, 1:5 dilution, 1:20 dilution). The optimal inoculation dose will then be selected and administered to all participants in each of the second and third CHMI.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. vivax infected inoculum (parasitised red blood cells)
Description: In the first controlled human malaria infection (CHMI, Phase A), inoculation of parasitised red blood cells will be at three different doses (1 vial, 1:5 dilution, 1:20 dilution). The optimal inoculation dose will then be selected and administered to all participants in each of the second and third CHMI.
Study: NCT04205656

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Concentrate (BMC)
Description: Participants will have a knee injected with BMC stem cells harvested from the iliac crest

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group (Placebo)
Description: Participants will undergo ACLR surgery with no injection into their knee.
Study: NCT03797989

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. vivax infected inoculum (parasitised red blood cells)
Description: In the first controlled human malaria infection (CHMI, Phase A), inoculation of parasitised red blood cells will be at three different doses (1 vial, 1:5 dilution, 1:20 dilution). The optimal inoculation dose will then be selected and administered to all participants in each of the second and third CHMI.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. vivax infected inoculum (parasitised red blood cells)
Description: In the first controlled human malaria infection (CHMI, Phase A), inoculation of parasitised red blood cells will be at three different doses (1 vial, 1:5 dilution, 1:20 dilution). The optimal inoculation dose will then be selected and administered to all participants in each of the second and third CHMI.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. vivax infected inoculum (parasitised red blood cells)
Description: In the first controlled human malaria infection (CHMI, Phase A), inoculation of parasitised red blood cells will be at three different doses (1 vial, 1:5 dilution, 1:20 dilution). The optimal inoculation dose will then be selected and administered to all participants in each of the second and third CHMI.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. vivax infected inoculum (parasitised red blood cells)
Description: In the first controlled human malaria infection (CHMI, Phase A), inoculation of parasitised red blood cells will be at three different doses (1 vial, 1:5 dilution, 1:20 dilution). The optimal inoculation dose will then be selected and administered to all participants in each of the second and third CHMI.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. vivax infected inoculum (parasitised red blood cells)
Description: In the first controlled human malaria infection (CHMI, Phase A), inoculation of parasitised red blood cells will be at three different doses (1 vial, 1:5 dilution, 1:20 dilution). The optimal inoculation dose will then be selected and administered to all participants in each of the second and third CHMI.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. vivax infected inoculum (parasitised red blood cells)
Description: In the first controlled human malaria infection (CHMI, Phase A), inoculation of parasitised red blood cells will be at three different doses (1 vial, 1:5 dilution, 1:20 dilution). The optimal inoculation dose will then be selected and administered to all participants in each of the second and third CHMI.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. vivax infected inoculum (parasitised red blood cells)
Description: In the first controlled human malaria infection (CHMI, Phase A), inoculation of parasitised red blood cells will be at three different doses (1 vial, 1:5 dilution, 1:20 dilution). The optimal inoculation dose will then be selected and administered to all participants in each of the second and third CHMI.
Study: NCT02308098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbuhaler 320/9 ug/inhalation 4 inh

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbuhaler 320/9 ug/inhalation 1inh

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh
Study: NCT00889837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Loxapine
Description: Staccato Loxapine, 10 mg x 2 doses, 10 hours apart

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Placebo
Description: Staccato Placebo, inhalations x 2 , 10 hours apart
Study: NCT03840109

Intervention type: BEHAVIORAL
Intervention: Questionnaire 1a
Description: Participants will be randomly shown two versions of messages in which the last 20% of the message consists of negative statements of criticism and rate of the effectiveness of the message.

Intervention type: BEHAVIORAL
Intervention: Questionnaire 1b
Description: Participants will be randomly shown two versions of messages in which the first 20% of the message consists of negative statements of criticism and rate of the effectiveness of the message.

Intervention type: BEHAVIORAL
Intervention: Questionnaire 2a
Description: Participants will be randomly shown two versions of messages in which the last 40% of the message consists of negative statements of criticism and rate of the effectiveness of the message.

Intervention type: BEHAVIORAL
Intervention: Questionnaire 2b
Description: Participants will be randomly shown two versions of messages in which the first 40% of the message consists of negative statements of criticism and rate of the effectiveness of the message.

Intervention type: BEHAVIORAL
Intervention: Questionnaire 3a
Description: Participants will be randomly shown two versions of messages in which the last 60% of the message consists of negative statements of criticism and rate of the effectiveness of the message.

Intervention type: BEHAVIORAL
Intervention: Questionnaire 3b
Description: Participants will be randomly shown two versions of messages in which the first 60% of the message consists of negative statements of criticism and rate of the effectiveness of the message.

Intervention type: BEHAVIORAL
Intervention: Questionnaire 4a
Description: Participants will be randomly shown two versions of messages in which the last 80% of the message consists of negative statements of criticism and rate of the effectiveness of the message.

Intervention type: BEHAVIORAL
Intervention: Questionnaire 4b
Description: Participants will be randomly shown two versions of messages in which the first 80% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
Study: NCT03109509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit + Pokemon Go
Description: Participants received a Fitbit Zip to wear daily for 8 weeks. Participants also received access to the Pokemon Go game.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Only
Description: Participants received a Fitbit Zip to wear daily for 8 weeks.
Study: NCT02080377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glibenclamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Study: NCT01743105

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diaphragm excursion measures 1
Description: A first diaphragm ultrasound study will be carried out by investigator 1. A Vivid S6 GE Ultrasound will be used, with a phased array cardiac probe.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diaphragm excursion measures 2
Description: A second diaphragm ultrasound study will be carried out immediately after Ultrasound 1, and by investigator 2. The results are blinded between investigators. A Vivid S6 GE Ultrasound will be used, with a phased array cardiac probe.
Study: NCT04811898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LNA-i-miR-221
Description: LNA-i-miR-221, IV daily infusion on days 1-4 followed by 24 days washout (1 cycle lasting 28 days)
Study: NCT04134715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06826647
Description: 100 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Contraceptive (OC)
Description: OC in the form of 1 PORTIA (30 µg EE and 150 µg LN) or equivalent tablet
Study: NCT04081389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT03797989

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. vivax infected inoculum (parasitised red blood cells)
Description: In the first controlled human malaria infection (CHMI, Phase A), inoculation of parasitised red blood cells will be at three different doses (1 vial, 1:5 dilution, 1:20 dilution). The optimal inoculation dose will then be selected and administered to all participants in each of the second and third CHMI.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. vivax infected inoculum (parasitised red blood cells)
Description: In the first controlled human malaria infection (CHMI, Phase A), inoculation of parasitised red blood cells will be at three different doses (1 vial, 1:5 dilution, 1:20 dilution). The optimal inoculation dose will then be selected and administered to all participants in each of the second and third CHMI.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. vivax infected inoculum (parasitised red blood cells)
Description: In the first controlled human malaria infection (CHMI, Phase A), inoculation of parasitised red blood cells will be at three different doses (1 vial, 1:5 dilution, 1:20 dilution). The optimal inoculation dose will then be selected and administered to all participants in each of the second and third CHMI.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. vivax infected inoculum (parasitised red blood cells)
Description: In the first controlled human malaria infection (CHMI, Phase A), inoculation of parasitised red blood cells will be at three different doses (1 vial, 1:5 dilution, 1:20 dilution). The optimal inoculation dose will then be selected and administered to all participants in each of the second and third CHMI.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. vivax infected inoculum (parasitised red blood cells)
Description: In the first controlled human malaria infection (CHMI, Phase A), inoculation of parasitised red blood cells will be at three different doses (1 vial, 1:5 dilution, 1:20 dilution). The optimal inoculation dose will then be selected and administered to all participants in each of the second and third CHMI.
Study: NCT01589809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotinamide
Description: dose-escalation, 2-8 grams, oral
Study: NCT01765608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Zonisamide (Zonegran®) tablets will be administered according to a forced stepwise weekly titration scheme with weekly 100 mg escalations from 100 to 300 mg daily according to the manufacturer Eisai Inc.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nCPAP
Study: NCT04081389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa-2b
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rintatolimod
Description: Given IV
Study: NCT02108626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: E-Cigarette with nicotine cartridge

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: E-Cigarette with 0mg nicotine cartridge
Study: NCT03980132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lugols Strong Iodine
Description: 5 L.I. drops / 8 hours for 10 days before surgery
Study: NCT01121536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Armodafinil tablets, taken orally, once daily in the morning